PuREC Partners With Mochida Pharmaceutical To Manufacture Its High-Purity Mesenchymal Stem Cells Towards The Treatment Of Metabolic Bone Diseases

PuREC (Headquarters: Shimane, Japan; President: Hideyuki Takahashi) announced its partnership with Mochida Pharmaceutical for manufacturing and process development of its high-purity mesenchymal stem cells (MSC), or ‘Rapidly Expanding Cells’ (REC), for the treatment of metabolic bone diseases and a wide range of other conditions. Tomo Anzai of Fast Track Initiative (hereinafter referred to as 'FTI') continues to support PuREC as an external BoD member through this partnership agreement.

To optimize MSC therapies, PuREC developed REC through a refined isolation method designed to identify and extract high-quality MSCs from human bone marrow. These cells exhibit excellent proliferative, differentiative, and migratory capabilities. Unlike conventional MSCs, REC offers higher efficacy while providing a safer and more consistent therapeutic option for stem cell therapy and future transplantation applications due to its performance and cellular homogeneity.

Both companies will advance the research and development of REC, originally developed by Dr. Yumi Matsuzaki, founder of PuREC and Professor at Shimane University. Under this partnership agreement, PuREC and Mochida will strategize around compliant manufacturing processes and establish a regulatory foundation for the future use of REC in regenerative medicine. They aim to accelerate development and achieve early commercialization of regenerative medicine products based on REC.

FTI has supported PuREC since its establishment in 2016 and looks forward to this partnership, which is expected to optimize stem cell therapy and transplantation in the treatment of bone diseases, autoimmune disorders, and more.

  About PuREC: PuREC is a bio-venture founded in 2016 by Yumi Matsuzaki, Professor at Shimane University, School of Medicine, conducting research and development to treat metabolic bone diseases by employing high-purity, Mesenchymal Stem Cells (MSC) to develop Rapidly Expanding Cells (REC). We are revolutionizing regenerative medicine technology that satisfies unmet medical needs using REC, which is produced by a refined isolation method from human bone marrow with excellent proliferative, differentiative, and migratory abilities. PuREC entered clinical trials for hypophosphatasia and spinal cord stenosis in 2021. For more information, please visit us on LinkedIn: https://www.linkedin.com/company/purecmsc/ or Facebook: https://www.facebook.com/purecjp/   About Fast Track Initiative: Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on grow seed and early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including diagnostics, digital health, healthcare services, and more. The company provides full, hands-on operational support to its 30+ portfolio companies through business and R&D strategy, investor syndication, and more, including access to their exclusive network of leading industry professionals in Japan. Visit https://us.fasttrackinitiative.com  for more details, or follow us on LinkedIn:  https://www.linkedin.com/company/fast-track-initiative/ For press inquiries or investor inquiries, please email:  message.us@fasttrackinitiative.com